Abstract Neonatal tumors comprise less than two percent of childhood malignancies. Most are solid tumors, most common histologies being teratoma and neuroblastoma. We encountered a child who was detected to have a right arm mass on antenatal sonogram, which was diagnosed to be a primitive neuroectodermal tumor involving the triceps on fine needle aspiration cytology performed in the post-natal period. The child was successfully treated with multimodality treatment consisting of surgery, chemotherapy and radiotherapy. We also discuss briefly the problems associated with therapy in neonatal period. A review of all cases reported to have congenital Ewing's sarcoma family of tumors is presented. Novel therapies are needed to improve efficacy and decrease the devastating side effects of treatment in this age group. ª 2014 Production and hosting by Elsevier B.V. on behalf
Introduction
Ewing's sarcoma family of tumors (ESFTs) is a group of tumors of neural crest origin, consisting of Ewing's sarcoma (ES), Askin's tumors, and peripheral primitive neuroectodermal tumors (pPNETs) [1] . Mean age at diagnosis is 15 years. With current multimodality regimens, five-year survival is 70% [2] . Neonatal presentation is rare, with 35 cases reported in the literature. We report an antenatally detected pPNET of triceps, successfully treated with multimodality therapy.
Case summary
A 13-month child presented to our department with a congenital right arm swelling. An antenatal maternal abdominal ultrasound (USG) at 37 weeks of gestation had shown a single live intrauterine fetus with no structural defects other than a 27 mm cystic subcutaneous right arm swelling ( Fig. 1a and  b) . He was delivered at term by Caesarian section for meconium stained liquor. No other congenital defects were noted. The child's developmental milestones were normal.
At one month, a 5 · 5 cm non-tender, cystic, freely mobile swelling was noted posterior to the right elbow, with warm but uninvolved skin and dilated superficial veins. No enlarged lymph nodes were noted. Doppler USG showed a hyperechoic mass with vascular periphery, and normal underlying bone and brachial artery. Fine needle aspiration cytology suggested malignant round cell tumor. The tumor was excised with clear resection margins. Intraoperatively, the mass was adherent to triceps and cut section showed hemorrhage and necrosis. [16] pPNET Sacrococcygeal region Histopathology revealed a well-encapsulated, globular mass (5.5 · 4 · 3 cm), closest margin being one centimeter. Immunohistochemistry showed MIC-2 positivity, and synaptophysin and leukocyte common antigen negativity. Overall features suggested pPNET of the right arm ( Fig. 2a-d) . Staging workup ruled out systemic metastases. Postoperative MRI did not show any tumor residuum or axillary nodes. He received 36 weeks of chemotherapy according to Pediatric Oncology Group/Children's Cancer Group (POG/CCG) protocol (VAC/IE), followed by adjuvant 3-D conformal tumor bed irradiation (6 MV photons, 45 Gray in 25 fractions), with no grade 3 or 4 morbidity. At seven years, he is disease-free, but has a comparative longitudinal limb shortening of two centimeters.
Discussion
Neonatal tumors comprise less than two percent of childhood malignancies, commonest histologies being teratoma and neuroblastoma. A high degree of genetic or syndromic association exists, although infections, maternal drug use and intrauterine ionizing radiation exposure may be responsible [3] .
ESFTs are characterized by uniform, densely packed, small round cells with round nucleoli-free nuclei and indistinct cytoplasm. They express immunohistochemical (MIC-2 gene) and genetic markers (t(11;22) and t(21;22) translocations), as well as a novel fusion protein EWS-FLI1, suggesting neural crest origin [1] . Congenital ESFT is a rare entity. Angervall and Enzinger described 39 soft tissue tumors indistinguishable from ES of bone including one case of a 20-month boy with a congenital paravertebral mass [4] . The child did not receive any treatment and was lost to follow up. Treatment details in a congenital chest wall PNET were first described by Das et al. in 1982 . Despite surgery, chemotherapy and radiotherapy, the child died of progressive disease after three months [5] . Other similar cases including ES or pPNET are mentioned in Table 1 . Eleven of these patients achieved complete remission, seven following multimodality treatment, and one had spontaneous regression of cutaneous nodules [6, [9] [10] [11] [12] 17, 23, 27, 28] .
Maygarden described 19 patients under three years with ES of bone, constituting 2.6% of all evaluable patients (19/734) registered in the five Intergroup ES Study protocols [32] . The most prominent differential in this age group is neuroblastoma, which can be distinguished by its neuron-specific enolase, Leu-7 and synaptophysin positivity, as well as N-myc amplification. There was a preponderance of females (p < 0.001) and a trend toward more proximal long bone, rib and pelvic tumors. All nineteen patients received chemotherapy and eighteen received radiotherapy. Overall survival (56%) matched with that in older children. Longest survival duration was 9.9 years. All disease-related deaths occurred within four years from diagnosis. Most prominent late morbidities in long-term survivors included post-radiation limb shortening in four children and adriamycin-related cardiotoxicity leading to cerebrovascular accident in one child.
In a recent NIH review, authors discuss various pertinent issues regarding congenital ESFT, namely, the truth to existence of such an entity, translocation-negative tumors, treatment options and outcome [33] . They quote three patients with round cell tumors initially misdiagnosed as other entities but later confirmed to have ESFT on molecular and immuno- , which have been assimilated in the current report as well; however three of these were diagnosed between three months and one year of age, and it is unclear if these were truly congenital. European Soft Tissue Sarcoma Group recommends avoiding ifosfamide in children younger than a month and anthracyclines in those under three months. Immature organs, delayed chemotherapy clearance and possibility of long-term treatment effects are valid concerns, but reports show that these children tolerate VAC-based therapy well. In a retrospective evaluation of bone sarcomas treated on various POG/CCG protocols , only nine out of 1156 patients developed solid second malignancies at a median follow-up of 6.1 years. All nine patients had received cyclophosphamide, etoposide and radiation. Since one-third patients die from disease, relapse prevention still remains the major goal of therapy [34] . Treatment protocols incorporating novel chemotherapeutic and molecular agents, sophisticated surgical techniques and efforts to minimize radiation dose and volumes may help refine existing measures to enable these children attain a healthy and productive adulthood.
To our knowledge, this is the first case of an antenatally diagnosed congenital PNET treated successfully with current ESFT protocol, establishing its safety even in younger children. The long-term adverse effects need to be borne in mind while planning therapy, but not at the cost of compromised survival.
